🇺🇸 FDA

Intelligence · Clinical Pipeline

NovoThirteen Pipeline

All ClinicalTrials.gov programs at NovoThirteen — phase, modality, and trial IDs.

Programs
94

Quick answer

NovoThirteen has 94 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

    NovoThirteen

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  2. Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    Chronic Kidney Disease, with or without Type 2 diabetes, Obesity

    phase 2 small molecule active

    1 trial

  3. Placebo A, Semaglutide B Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen

    NovoThirteen

    type 2 diabetes

    phase 2 small molecule active

    1 trial

  4. Placebo C, Semaglutide B 3.0 mg/ml PDS290, Semaglutide B placebo PDS290 pen-injector, Cagrilintide A 10 mg/mL cartridge, NNC0174-0833 A Placebo

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  5. Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    NovoThirteen

    SGA - small for gestational age children

    phase 2 small molecule active

    1 trial

  6. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide

    NovoThirteen

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  7. cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, Placebo (zalfermin) + Placebo (semaglutide), semaglutide, Placebo (cagrilintide) + placebo (semaglutide), cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, cagrilintide, cagrilintide semaglutide, zalfermin, cagrilintide, cagrilintide

    NovoThirteen

    alcohol-related liver disease

    phase 2 small molecule active

    1 trial

  8. etavopivat B 10041, etavopivat B 10042

    NovoThirteen

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  9. A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

    NovoThirteen

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  10. A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function

    NovoThirteen

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  11. A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity

    NovoThirteen

    Type 2 diabetes mellitus

    phase 1 other active

    1 trial

  12. A research study investigating the effect of NNC0497-0040 in healthy participants, participants with overweight or obesity, and participants with type 1 diabetes with overweight or obesity.

    NovoThirteen

    Type I diabetes

    phase 1 other active

    1 trial

  13. A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity

    NovoThirteen

    Participants with obesity, but otherwise healthy

    phase 1 other active

    1 trial

  14. A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A

    NovoThirteen

    Haemophilia A with or without inhibitors. Proposed indication under development: prevention of bleeding and long-term prophylaxis in patients with haemophilia A, irrespective of inhibitor status or severity.

    phase 1 other active

    1 trial

  15. A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men.

    NovoThirteen

    Prophylaxis and on-demand treatment respectively in patients with haemophilia A with or without FVIII inhibitors.

    phase 1 other active

    1 trial

  16. A research study looking into blood levels of the medicine NNC0487 0111 in the body and how well it is tolerated in people with reduced liver function and normal liver function

    NovoThirteen

    hepatic impairment

    phase 1 other active

    1 trial

  17. A research study looking into how cagrilintide influences food intake and appetite in people with overweight or obesity

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  18. A research study looking into the effect of NNC05190130 on blood levels of a birth control pill and emptying of the stomach in women after menopause

    NovoThirteen

    Healthy postmenopausal females (Type 2 Diabetes)

    phase 1 other active

    1 trial

  19. A research study of a new medicine (NNC0650-0013) in healthy men

    NovoThirteen

    Weight management, Diabetes mellitus type 2; healthy subjects

    phase 1 other active

    1 trial

  20. A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes

    NovoThirteen

    Type 1 diabetes mellitus

    phase 1 other active

    1 trial

  21. A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes

    NovoThirteen

    Diabetes type 1

    phase 1 other active

    1 trial

  22. A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes

    NovoThirteen

    Healthy Participants and Participants with type 2 diabetes

    phase 1 other active

    1 trial

  23. A research study of how safe a new medicine called NNC0519‑0130 is and to test its effect in people living with excess body weight with or without type 2 diabetes

    NovoThirteen

    Obesity, Type 2 Diabetes with either overweight or obesity

    phase 1 other active

    1 trial

  24. A research study on the effects of NNC0537-1482 in healthy individuals when injected under the skin.

    NovoThirteen

    Heart Failure

    phase 1 other active

    1 trial

  25. A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

    NovoThirteen

    obesity

    phase 1 other active

    1 trial

  26. A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemochromatosis type 1.

    NovoThirteen

    Hereditary haemochromatosis (HH) type 1

    phase 1 other active

    1 trial

  27. A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

    NovoThirteen

    Healthy participants and participants with type 2 diabetes

    phase 1 other active

    1 trial

  28. A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  29. A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people with ATTR amyloidosis

    NovoThirteen

    transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)

    phase 1 other active

    1 trial

  30. A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  31. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  32. A study of how CagriSema works on appetite in people with excess body weight

    NovoThirteen

    Obesity

    phase 1 other active

    1 trial

  33. A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabetes.

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  34. A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  35. A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  36. A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  37. A study understanding how much CDR132L enters the bloodstream after injection under the skin compared to injection into a vein in healthy participants

    NovoThirteen

    Healthy volunteers, treatment for heart failure

    phase 1 other active

    1 trial

  38. Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  39. Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

    NovoThirteen

    Type 2 Diabetes

    phase 1 other active

    1 trial

  40. Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults

    NovoThirteen

    Healthy Volunteers

    phase 1 other active

    1 trial

  41. Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

    NovoThirteen

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  42. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  43. Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health

    NovoThirteen

    Obesity, CCI, CCI

    phase 1 other active

    1 trial

  44. Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution

    NovoThirteen

    Type 2 diabetes

    approved small molecule active

    1 trial

  45. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen

    NovoThirteen

    Obesity

    approved small molecule active

    1 trial

  46. cagrilintide, Placebo + Placebo, semaglutide, cagrilintide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, cagrilintide semaglutide, semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide, cagrilintide

    NovoThirteen

    Obesity and T2D

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does NovoThirteen have?

94 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.